Home › Research › Biomarkers
Real-world applicability of glial fibrillary acidic protein and neurofilament light chain in Alzheimer's disease
Tandis Parvizi, Theresa König, Raphael Wurm, Sara Silvaieh, Patrick Altmann, Sigrid Klotz, Paulus Stefan Rommer, Julia Furtner et al.. Frontiers in aging neuroscience, 2022-08-22
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
We constructed a panel combining plasma NfL and GFAP with known AD risk factors (Combination panel: age+sex+APOE4+GFAP+NfL). With an AUC of 91.6% (95%CI = 0.85-0.98) for HC vs. AD and 81.7% (95%CI = 0.73-0.90) for HC vs. MCI as well as an AUC of 87.5% (95%CI = 0.73-0.96) in terms of predicting amyloid positivity, this panel showed a promising discriminatory power to differentiate these populations. The combination of plasma GFAP and NfL with well-established risk factors discerns amyloid positive from negative patients and could potentially be applied to identify patients who would benefit from a more invasive assessment of amyloid pathology. In the future, improved prediction of amyloid positivity with a noninvasive test may decrease the number and costs of a more invasive or expensive diagnostic approach.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Parvizi, T., König, T., Wurm, R., Silvaieh, S., Altmann, P., Klotz, S., et al. (2022). Real-world applicability of glial fibrillary acidic protein and neurofilament light chain in Alzheimer's disease. Frontiers in aging neuroscience. https://doi.org/10.3389/fnagi.2022.887498
Vancouver
Parvizi T, König T, Wurm R, Silvaieh S, Altmann P, Klotz S, et al. Real-world applicability of glial fibrillary acidic protein and neurofilament light chain in Alzheimer's disease. Frontiers in aging neuroscience. 2022. doi:10.3389/fnagi.2022.887498. PMID: 36072480.
BibTeX
@article{parvizi2022-36072480,
author = {Parvizi, Tandis and König, Theresa and Wurm, Raphael and Silvaieh, Sara and Altmann, Patrick and Klotz, Sigrid and Rommer, Paulus Stefan and Furtner, Julia and others},
title = {{Real-world applicability of glial fibrillary acidic protein and neurofilament light chain in Alzheimer's disease}},
journal = {Frontiers in aging neuroscience},
year = {2022},
doi = {10.3389/fnagi.2022.887498},
pmid = {36072480},
url = {https://doi.org/10.3389/fnagi.2022.887498}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- We constructed a panel combining plasma NfL and GFAP with known AD risk factors (Combination panel: age+sex+APOE4+GFAP+NfL).
- With an AUC of 91.6% (95%CI = 0.85-0.98) for HC vs.
- AD and 81.7% (95%CI = 0.73-0.90) for HC vs.
- MCI as well as an AUC of 87.5% (95%CI = 0.73-0.96) in terms of predicting amyloid positivity, this panel showed a promising discriminatory power to differentiate these populations.
- The combination of plasma GFAP and NfL with well-established risk factors discerns amyloid positive from negative patients and could potentially be applied to identify patients who would benefit from a more invasive assessment of amyloid pathology.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcross-sectional
- Participants63
- Effect size91.6%; 81.7%; 87.5%
- Evidence strengthLow
How this study scored 59/100
Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 33 of the 56 points we could judge it on, which is 59 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Frontiers in aging neuroscience) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 63 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 36072480) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 33 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 33 of the 56 points we could judge it on is 59 out of 100. |
| Total | 59 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “p-tau217”
692 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 692 tagged studies.